Martin, T., Richter, J., Vij, R., Cole, C., Atanackovic, D., Zonder, J., … Mikhael, J. (2015). A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.

Martin, Thomas, Joshua Richter, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey Zonder, Jonathan L. Kaufman, et al. “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.

Martin T, Richter J, Vij R, Cole C, Atanackovic D, Zonder J, et al. A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. In: BLOOD. AMER SOC HEMATOLOGY; 2015.

Martin, Thomas, et al. “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.

Martin T, Richter J, Vij R, Cole C, Atanackovic D, Zonder J, Kaufman JL, Bensinger W, Dimopoulos MA, San Miguel J, Zimmerman T, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Hsu K, Charpentier E, Strickland SA, Mikhael J. A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY; 2015.